Newsletter Archive

21. 06.11.24 -- What You Should Know About The FDA's New Final Rule On LDTs 6/11/2024
    06/11/24 Laboratory Network Newsletter
22. 05.28.24 -- New FDA Draft Guidance: Data Integrity For In Vivo Bioavailability And Bioequivalence Studies 5/28/2024
    05/28/24 Laboratory Network Newsletter
23. 05.14.24 -- Cell Counting Is Growing More Important Amid Advanced Therapy's Rise 5/14/2024
    05/14/24 Laboratory Network Newsletter
24. 04.23.24 -- FDA Warns Industry Of Fraudulent & Unreliable Lab Testing Data In Premarket Submissions 4/23/2024
    04/23/24 Laboratory Network Newsletter
25. 04.09.24 -- Pivoting To Allogeneic CAR-T Therapies With Celyad Oncology's CMO, Dr. Charlie Morris 4/9/2024
    04/09/24 Laboratory Network Newsletter
26. 03.26.24 -- Notable Public Comments On The FDA's Proposed Regulation For Laboratory Developed Tests 3/26/2024
    03/26/24 Laboratory Network Newsletter
27. 03.12.24 -- FDA's CBER Issues Final Guidance For CAR T Cell Products 3/12/2024
    03/12/24 Laboratory Network Newsletter
28. 02.27.24 -- FDA Issues Final Guidance: Reformulating Drug Products That Contain Carbomers Manufactured With Benzene 2/27/2024
    02/27/24 Laboratory Network Newsletter
29. 02.13.24 -- FDA Issues Draft Guidance For Cell & Gene Therapy Potency Assurance 2/13/2024
    02/13/24 Laboratory Network Newsletter
30. 01.23.24 -- 4 Strategies To Formulate Poorly Soluble APIs 1/23/2024
    01/23/24 Laboratory Network Newsletter